Ipamorelin & CJC-1295: The Safe Stack for Growth Hormone Optimisation

Why GH Declines and Why It Matters

Growth hormone secretion follows a predictable age-related decline. Peak GH output occurs in the second decade of life. By age 40, total GH secretion has declined by approximately 50%. By age 60, it may be 80% below youthful levels.

The consequences extend beyond muscle and fat composition. Growth hormone plays roles in:

• Sleep architecture: GH secretion is tightly coupled to slow-wave sleep; GH decline contributes to reduced sleep quality with age
• Tissue repair: The majority of soft tissue repair occurs during GH-stimulated sleep windows
• Cognitive function: GH receptors in the hippocampus and frontal cortex influence memory and executive function
• Immune function: GH modulates thymic activity and natural killer cell function

The pharmaceutical approach to GH decline is direct recombinant HGH injection — expensive, requiring prescription, and producing supraphysiological GH levels with attendant side effects. The Ipamorelin + CJC-1295 approach is different: it amplifies the body's own pulsatile GH secretion rather than replacing it.

The Two Receptor Pathways

The pituitary's GH-secreting somatotrophs have two distinct receptor types relevant to secretagogue peptides:

GHRH receptor (activated by CJC-1295): When stimulated, increases cAMP and prepares the somatotroph's secretory granules for release. Think of this as "loading the gun" — building up the GH available to be released.

GHSR (Ghrelin receptor) (activated by Ipamorelin): When stimulated, triggers the actual release of pre-formed GH secretory granules. Think of this as "pulling the trigger."

Activating both pathways simultaneously — which is what the combined stack does — produces a GH pulse 3-5x greater than activating either pathway alone. ^[] This synergism is the mechanistic foundation of the stack.

Ipamorelin vs Other GHRPs

| GHRP | GH Stimulation | Cortisol | Prolactin | Receptor Selectivity | |---|---|---|---|---| | GHRP-2 | Strong | Yes (+75%) | Yes | Non-selective | | GHRP-6 | Strong | Yes (+60%) | Yes | Non-selective | | Hexarelin | Very strong | Yes (+100%) | Yes | Rapid desensitisation | | Ipamorelin | Moderate | No | No | Highly selective |

Ipamorelin produces less absolute GH stimulation than GHRP-2 or Hexarelin — but it does so without the cortisol and prolactin elevation that make the others problematic for sustained use. Over a 12-16 week cycle, the cumulative advantage of clean GH stimulation without cortisol suppression of its benefits is substantial. ^[]

Why Pre-Sleep Fasted Injection Is Critical

The body's largest natural GH pulse occurs during the first cycle of slow-wave sleep — typically 30-90 minutes after sleep onset. This is when 70-80% of the day's total GH secretion occurs, and when the majority of GH-mediated repair processes are initiated. ^[]

Injecting Ipamorelin + CJC-1295 30-60 minutes before sleep amplifies this natural pulse at the physiologically correct time. The fasted state is mandatory: insulin (elevated after meals) suppresses GH secretion by increasing somatostatin tone. Studies show post-meal insulin can reduce GHRH-stimulated GH release by up to 70%.

Rule: Last meal at least 2-3 hours before injection. No protein shakes or carbohydrates after injection until the morning. Water and electrolytes are fine.

Standard Protocol

Nightly injection (30-60 min before sleep, fasted):

• Ipamorelin: 100-200mcg subcutaneous
• CJC-1295 (no DAC): 100mcg subcutaneous
• Inject both simultaneously, any subcutaneous site

Cycle: 12-16 weeks on, 4-8 weeks off

Reconstitution:

• Ipamorelin 5mg vial + 2.5ml bacteriostatic water = 2mg/ml. 200mcg dose = 0.1ml
• CJC-1295 5mg vial + 2.5ml bacteriostatic water = 2mg/ml. 100mcg dose = 0.05ml

Adding to the Wolverine Stack

The Ipamorelin + CJC-1295 combination adds a third layer to the Wolverine Stack:

1. BPC-157 — local tissue repair environment
2. TB-500 — systemic repair cell mobilisation
3. Ipamorelin + CJC-1295 — elevated GH during sleep amplifies the repair processes that layers 1 and 2 have initiated

BPC-157 specifically upregulates GH receptors in healing tissue — so the elevated GH produced by Ipamorelin + CJC-1295 has more sensitive targets to work on. The interaction is mechanistically sound and consistently reported as additive in the practitioner community.